Disulfiram ameliorates STING/MITA-dependent inflammation and autoimmunity by targeting RNF115.
Zhi-Dong ZhangChang-Rui ShiFang-Xu LiHu GanYanhong WeiQianhui ZhangXin ShuaiMin ChenYu-Lin LinTian-Chen XiongXiaoqi ChenBo ZhongDandan LinPublished in: Cellular & molecular immunology (2024)
STING (also known as MITA) is an adaptor protein that mediates cytoplasmic DNA-triggered signaling, and aberrant activation of STING/MITA by cytosolic self-DNA or gain-of-function mutations causes severe inflammation. Here, we show that STING-mediated inflammation and autoimmunity are promoted by RNF115 and alleviated by the RNF115 inhibitor disulfiram (DSF). Knockout of RNF115 or treatment with DSF significantly inhibit systemic inflammation and autoimmune lethality and restore immune cell development in Trex1 -/- mice and STING N153S/WT bone marrow chimeric mice. In addition, knockdown or pharmacological inhibition of RNF115 substantially downregulate the expression of IFN-α, IFN-γ and proinflammatory cytokines in PBMCs from patients with systemic lupus erythematosus (SLE) who exhibit high concentrations of dsDNA in peripheral blood. Mechanistically, knockout or inhibition of RNF115 impair the oligomerization and Golgi localization of STING in various types of cells transfected with cGAMP and in organs and cells from Trex1 -/- mice. Interestingly, knockout of RNF115 inhibits the activation and Golgi localization of STING N153S as well as the expression of proinflammatory cytokines in myeloid cells but not in endothelial cells or fibroblasts. Taken together, these findings highlight the RNF115-mediated cell type-specific regulation of STING and STING N153S and provide potential targeted intervention strategies for STING-related autoimmune diseases.
Keyphrases
- bone marrow
- dna damage response
- endothelial cells
- randomized controlled trial
- dendritic cells
- peripheral blood
- multiple sclerosis
- immune response
- systemic lupus erythematosus
- high fat diet induced
- cell cycle arrest
- single molecule
- type diabetes
- wild type
- acute myeloid leukemia
- rheumatoid arthritis
- early onset
- mouse model
- metabolic syndrome
- small molecule
- long non coding rna
- cell therapy
- dna damage
- disease activity
- skeletal muscle
- combination therapy
- smoking cessation
- replacement therapy